PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
BackgroundProstate specific membrane antigen (PSMA) PET imaging has recently gained attention in glioblastoma (GBM) patients as a potential theranostic target for PSMA radioligand therapy. However, PSMA PET has not yet been established in a murine GBM model. Our goal was to investigate the potential...
Guardado en:
Autores principales: | Maximilian A. Kirchner, Adrien Holzgreve, Matthias Brendel, Michael Orth, Viktoria C. Ruf, Katja Steiger, Dennis Pötter, Lukas Gold, Marcus Unterrainer, Lena M. Mittlmeier, Enio Barci, Roland E. Kälin, Rainer Glass, Simon Lindner, Lena Kaiser, Jessica Maas, Louisa von Baumgarten, Harun Ilhan, Claus Belka, Johannes Notni, Peter Bartenstein, Kirsten Lauber, Nathalie L. Albert |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a33fdca79420480f90602dfda9688c64 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study
por: Jarosław B. Ćwikła, et al.
Publicado: (2021) -
Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach
por: Hanane Lahnif, et al.
Publicado: (2021) -
Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Kristin A. Plichta, et al.
Publicado: (2021) -
Prognostic Role of Interleukin-23 in Prostate Adenocarcinoma: Comparison with Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography Findings
por: Cihan Gündoğan, et al.
Publicado: (2021) -
Prognostic Value of Vascular-Expressed PSMA and CD248 in Urothelial Carcinoma of the Bladder
por: Yu Li, et al.
Publicado: (2021)